MicroRNA‑154 functions as a tumor suppressor in non‑small cell lung cancer through directly targeting B‑cell‑specific Moloney murine leukemia virus insertion site 1

Liu,Sida; Yang,Yang; Chen,Lu; Liu,Danwei; Dong,Han

doi:10.3892/ol.2018.8595

MicroRNA‑154 functions as a tumor suppressor in non‑small cell lung cancer through directly targeting B‑cell‑specific Moloney murine leukemia virus insertion site 1

Authors:
- Sida Liu
- Yang Yang
- Lu Chen
- Danwei Liu
- Han Dong
View Affiliations

Affiliations: Department of Thoracic Surgery, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China, Department of Tumor and Blood Disease, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin 130021, P.R. China, Department of Infectious, People's Hospital of Jilin, Changchun, Jilin 130021, P.R. China, Department of Geratology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: April 27, 2018 https://doi.org/10.3892/ol.2018.8595
Pages: 10098-10104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer remains the leading cause of cancer‑associated mortality in China and worldwide. Increasing numbers of studies have demonstrated that microRNAs (miRNAs/miRs) have vital functions in numerous developmental processes and tumorigenesis. The aim of the present study was to investigate miR‑154 expression in non‑small cell lung cancer (NSCLC), and to explore the roles of miR‑154 in the carcinogenesis and progression of this cancer. Reverse transcription‑polymerase chain reaction (RT‑qPCR) was performed to detect miR‑154 expression in NSCLC tissues and cell lines. In addition, cell proliferation assay, migration and invasion assays were adopted to investigate the functional roles of miR‑154 in NSCLC. Bioinformatics analysis, luciferase reporter assay, RT‑qPCR and western blot analysis were used to explore the potential targets of miR‑154 in NSCLC. According to the results, miR‑154 was significantly downregulated in NSCLC tissues and cell lines. Restoration of miR‑154 expression inhibited proliferation, migration and invasion of NSCLC cells. In addition, B‑cell‑specific Moloney murine leukemia virus insertion site 1 (BMI‑1) was identified as a direct target gene of miR‑154 in NSCLC. In conclusion, miR‑154 may function as a tumor suppressor in NSCLC, partly by regulating BMI‑1, and the modulation of miR‑154 expression represents a potential strategy for the treatment of NSCLC patients.

View Figures

View References

1	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
2	Yang L, Parkin DM, Li L and Chen Y: Time trends in cancer mortality in China: 1987–1999. Int J Cancer. 106:771–783. 2003. View Article : Google Scholar : PubMed/NCBI
3	Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 350:379–392. 2004. View Article : Google Scholar : PubMed/NCBI
4	Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer. Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
5	de Cos Sánchez J, González Sojo MA, Montero MV, Calvo Pérez MC, Vicente MJ and Valle MH: Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer. 63:140–145. 2009. View Article : Google Scholar : PubMed/NCBI
6	Chen T, Xu C, Chen J, Ding C, Xu Z, Li C and Zhao J: MicroRNA-203 inhibits cellular proliferation and invasion by targeting Bmi1 in non-small cell lung cancer. Oncol Lett. 9:2639–2646. 2015. View Article : Google Scholar : PubMed/NCBI
7	Hou Y, Zhen J, Xu X, Zhen K, Zhu B, Pan R and Zhao C: miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer. Oncol Lett. 10:1985–1992. 2015. View Article : Google Scholar : PubMed/NCBI
8	Li D, Wei Y, Wang D, Gao H and Liu K: MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-kappaB/MMP-9/VEGF pathways. Biochem Biophys Res Commun. 472:465–470. 2016. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Engels BM and Hutvagner G: Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene. 25:6163–6169. 2006. View Article : Google Scholar : PubMed/NCBI
11	Aigner A: MicroRNAs (miRNAs) in cancer invasion and metastasis: Therapeutic approaches based on metastasis-related miRNAs. J Mol Med (Berl). 89:445–457. 2011. View Article : Google Scholar : PubMed/NCBI
12	Rottiers V and Näär AM: MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 13:239–250. 2012. View Article : Google Scholar : PubMed/NCBI
13	Cho WC: MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
14	Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y and Yu W: miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett. 586:3761–3765. 2012. View Article : Google Scholar : PubMed/NCBI
15	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
16	Celli BR: Chronic obstructive pulmonary disease and lung cancer: Common pathogenesis, shared clinical challenges. Proc Am Thorac Soc. 9:74–79. 2012. View Article : Google Scholar : PubMed/NCBI
17	Jiang YW and Chen LA: microRNAs as tumor inhibitors, oncogenes, biomarkers for drug efficacy and outcome predictors in lung cancer (review). Mol Med Rep. 5:890–894. 2012. View Article : Google Scholar : PubMed/NCBI
18	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
19	Mishra PJ and Merlino G: MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest. 119:2119–2123. 2009.PubMed/NCBI
20	Kai Y, Qiang C, Xinxin P, Miaomiao Z and Kuailu L: Decreased miR-154 expression and its clinical significance in human colorectal cancer. World J Surg Oncol. 13:1952015. View Article : Google Scholar : PubMed/NCBI
21	Lin X, Yang Z, Zhang P and Shao G: miR-154 suppresses non-small cell lung cancer growth in vitro and in vivo. Oncol Rep. 33:3053–3060. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zhou H, Zhang M, Yuan H, Zheng W, Meng C and Zhao D: MicroRNA-154 functions as a tumor suppressor in osteosarcoma by targeting Wnt5a. Oncol Rep. 35:1851–1858. 2016. View Article : Google Scholar : PubMed/NCBI
23	Pang X, Huang K, Zhang Q, Zhang Y and Niu J: miR-154 targeting ZEB2 in hepatocellular carcinoma functions as a potential tumor suppressor. Oncol Rep. 34:3272–3279. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, Ju X, Meng X, et al: miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells. Mol Cell Biochem. 379:69–75. 2013. View Article : Google Scholar : PubMed/NCBI
25	Xin C, Zhang H and Liu Z: miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2. Mol Cell Biochem. 387:271–277. 2014. View Article : Google Scholar : PubMed/NCBI
26	Zhu C, Shao P, Bao M, Li P, Zhou H, Cai H, Cao Q, Tao L, Meng X, Ju X, et al: miR-154 inhibits prostate cancer cell proliferation by targeting CCND2. Urol Oncol. 32:31.e9–e16. 2014. View Article : Google Scholar